FDA to assess Merck's intravenous anti-infective drug

11/18/2013 | eMPR.com

The FDA will conduct a priority review of Merck & Co.'s new drug application for an intravenous solution of posaconazole, an antifungal drug. The oral solution of posaconazole was approved to prevent Aspergillus and Candida infections in immunocompromised patients who underwent stem cell transplants and developed graft-versus-host disease and those with neutropenia caused by chemotherapy.

View Full Article in:

eMPR.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX